Related Experiment Video
Updated: May 20, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABAA receptor positive allosteric
Anne Louise Stewart1, Eleanor Blair Towers2, Elizabeth S Wenzel1
1Department of Psychiatry and Neurobehavioral Sciences, University of Virgina, Charlottesville, VA, USA.
Introduction:
Postpartum depression (PPD) is a common psychiatric illness with significant consequences for both mother and infant. The approval of brexanolone in 2019 introduced a novel mechanism of antidepressant action targeting the gamma-aminobutyric acid type A receptor (GABAAR) through neuroactive steroids (NASs), highlighting the role of GABAergic and stress-axis dysregulation in PPD.
Areas Covered:
This review summarizes current understanding of NAS biology and GABAAR modulation in the pathophysiology of PPD, including the GABAergic deficit hypothesis and the impact of peripartum hormonal fluctuations. We review clinical trial data supporting the efficacy, safety, and rapid onset of brexanolone and zuranolone, as well as their sustained antidepressant effects. In addition, we discuss emerging NAS-based therapeutics and preclinical models demonstrating the role of GABAergic plasticity and stress-axis regulation in PPD. Literature was identified through review of clinical, observational, and preclinical studies relevant to NAS signaling and GABAergic function.
Expert Opinion:
Positive allosteric modulators of GABAAR represent a novel and promising approach to the treatment of PPD, with rapid and sustained antidepressant effects. These agents may ultimately have broader applications across psychiatric disorders characterized by GABAergic dysfunction, although further research is needed to clarify their role and optimize their use.
More Related Videos
07:58Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
Published on: February 24, 2023
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
G-protein Coupled Receptors
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antidepressant Drugs: Overview
Ligand-Gated Ion Channel Receptor: Gating Mechanism